Foundayo

Eli Lilly's drug, Foundayo, has won approval in the U.K., extending its participation in the weight-loss pill battle beyond the U.S. market. This development intensifies the competition between Eli Lilly and Novo Nordisk regarding their respective treatments.

CVS exceeded estimates and raised guidance due to improvements in its insurance unit. The company announced a collaboration with Eli Lilly to make Zepbound and Foundayo accessible to eligible patients via the CVS Health app.

Eli Lilly's obesity drug retatrutide showed significant weight loss in a Phase 3 study but did not reduce cardiovascular risk. The U.S. Medicare program is offering injectable GLP-1 obesity medications like Wegovy, Foundayo, and Zepbound through a trial program for $50 monthly, with high patient demand for injectables despite expectations of pill preference.

The ACHIEVE-5 trial demonstrated that adding oral orforglipron (Foundayo) to basal insulin improved glycemic control and reduced body weight in diabetes patients. The results were presented at the American Diabetes Association annual meeting.

Medicare is offering select GLP-1 weight loss drugs for $50/month through a temporary trial until 2027, with eligibility based on BMI and specific health conditions. Covered medications include Eli Lilly's Foundayo and Zepbound, and Novo Nordisk's Wegovy, but exclusions apply for those with diabetes or sleep apnea.

Medicare will cover GLP-1 weight-loss treatments through a temporary pilot program starting July 1, allowing eligible participants to pay a $50 monthly co-pay. The program includes Eli Lilly’s Zepbound and Foundayo and Novo Nordisk’s Wegovy, with coverage ending by 2027 due to federal law restrictions. Eligibility requires a BMI of 35 or higher (or 30 with specific health conditions), and prior authorization is needed.

Some employers plan to drop coverage of GLP-1 weight loss drugs in 2027 as usage rises, despite lower prices for medications like Novo Nordisk’s Zepbound and Eli Lilly’s Foundayo. Rapid adoption of GLP-1 drugs in the U.K. has reduced annual grocery spending by $1 billion, with 6.3% of households now including at least one user.

The Wegovy pill continues to be a leading choice for weight loss in the GLP-1 pill market in the U.S., maintaining its dominance despite the introduction of Foundayo, Eli Lilly’s competing GLP-1 pill.

CVS will cover Lilly’s GLP-1 medications, Foundayo (a pill) and Zepbound (an injection), potentially expanding access for millions of Americans.

The article discusses upcoming public visibility of drug prices under Trump's most-favored-nation deals, highlighting three new drugs (Baxfendy, Awiqli, and Veppanu). CVS Health is reintroducing Eli Lilly's obesity drug Zepbound to formularies and removing coverage restrictions on Lilly's new weight loss pill Foundayo.

CVS Health will add Zepbound coverage starting October 1 and begin covering Eli Lilly's newly approved obesity treatment, Foundayo, on June 1. The moves expand drug plan accessibility for weight management medications.

Eli Lilly has developed an experimental weight loss injection that achieved 28% weight loss in trials. The new shot differs from existing medications Zepbound and Foundayo by combining three active components: GIP, GLP-1, and glucagon.

US Food and Drug Administration Commissioner Marty Makary is resigning, with Kyle Diamantas stepping in as acting commissioner. Eli Lilly's weight loss pill Foundayo was found to have patients regain an average of 2-11 pounds after switching from injectable medications. The FDA has been marked by personnel drama and controversy over political pressure.

The FDA has requested additional safety data from Eli Lilly regarding its GLP-1 weight loss medication Foundayo. This follows regulatory scrutiny of the drug's safety profile for potential approval.